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Abstract
Background:  A software based tool has been developed (Optem) to allow automatize the
recommendations of the Canadian Multiple Sclerosis Working Group for optimizing MS treatment
in order to avoid subjective interpretation.
Methods: Treatment Optimization Recommendations (TORs) were applied to our database of
patients treated with IFN β1a IM. Patient data were assessed during year 1 for disease activity, and
patients were assigned to 2 groups according to TOR: "change treatment" (CH) and "no change
treatment" (NCH). These assessments were then compared to observed clinical outcomes for
disease activity over the following years.
Results: We have data on 55 patients. The "change treatment" status was assigned to 22 patients,
and "no change treatment" to 33 patients. The estimated sensitivity and specificity according to last
visit status were 73.9% and 84.4%. During the following years, the Relapse Rate was always higher
in the "change treatment" group than in the "no change treatment" group (5 y; CH: 0.7, NCH: 0.07;
p < 0.001, 12 m – last visit; CH: 0.536, NCH: 0.34). We obtained the same results with the EDSS
(4 y; CH: 3.53, NCH: 2.55, annual progression rate in 12 m – last visit; CH: 0.29, NCH: 0.13).
Conclusion: Applying TOR at the first year of therapy allowed accurate prediction of continued
disease activity in relapses and disability progression.
Background
Disease Modifying Treatments (DMTs) give neurologists a
tool for treating multiple sclerosis (MS). There is evidence
that these DMTs reduce disease activity and change the
natural course of MS, but in clinical practice it is difficult
to control the magnitude of the treatment effect and to
evaluate treatment responsiveness in concrete cases. Cur-
rently, clinicians do not have criteria for defining subopti-
mal responses.
The Canadian Multiple Sclerosis Working Group
(CMSWG) developed practical recommendations [1] on
how neurologists should assess the status of patients on
DMT and help them to decide when optimizing treatment
might be necessary. Nevertheless, these recommendations
need prospective validation.
We have developed a software based tool to allow us score
the recommendations of the CMSWG, avoiding a subjec-
tive interpretation of the results, using disease status
assessments. Our objectives are (a) to validate the Treat-
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ment Optimization Recommendations (TORs) estab-
lished by the CMSWG, using an automatic program
developed by our group in application to a Spanish pop-
ulation of definite relapsing-remitting MS (RRMS)
patients initially treated with interferon beta 1a, 30 mg/
week IM; and (b) to evaluate whether TOR disease status
assessments (based on relapses and disability progres-
sion) after one year of treatment with low dose interferon
beta 1a can predict clinical outcomes after years of treat-
ment.
Methods
Study population
We reviewed 55 patients from the database of the MS
Clinic of Hospital Universitario Virgen Macarena (Seville,
Spain) who were diagnosed of RRMS according to the cri-
teria of Poser et al [2], and treated with Interferon β 1a IM
30 mg/week. These patients started treatment between
January 1998 and May 2004, and were subjected to pro-
spective follow-up. Patients were evaluated at least four
times a year to assess disability, and the number and
severity of relapses. Disability was measured by trained
neurologists using Kurtzke's EDSS [3]. All patients gave
written informed consent for storage of their data in a cen-
tral database for research purposes and the study was
approved by the hospital's ethical committee.
Optem
Optem is a software tool developed by our group, allow-
ing easy and objective automatic optimization of treat-
ment changes based on the CMSWG criteria. The program
comprises three screens – one for each field examined:
attacks, progression and magnetic resonance imaging. On
completing these fields, the program automatically devel-
ops a risk report based on the information supplied in
each screen. Following the optimization criteria of the
CMSWG, and concluding whether the patient must be
optimized towards other treatment or can continue with
the current therapy.
In the screen "attacks" the application assesses 3 parame-
ters: relapse reduction, relapse recovery and severity, scor-
ing from 0 to 3 points according to null, low, medium or
high level.
In order to determine the relapse reduction, the software
calculates the "annual relapse rate" for each period. The
number of relapses is registered for each period and is
considered to be "Low" for a relapse rate reduction
between 75 and 99%, "medium" for a relapse rate reduc-
tion between 35 to 74% and "high" if the result ranges
between a 0 and 34%.
Relapse recovery is considered to be "low" if there is a
prompt recovery, "medium" if recovery is incomplete at 3
months and "high" if recovery is not complete at 6
months.
Relapse severity is considered to be "mild", "moderate" or
"serious" depending on corticosteroids use, hospitaliza-
tion, functional systems affected and activities of daily liv-
ing.
In the screen "progression", disability progression is
assessed under two categories: EDSS and clinical progres-
sion. It is considered low, medium or high with according
to EDSS progression and the presence of sensitive, motor,
cerebellar or cognitive symptoms.
The screen "MRI" evaluates changes in imaging parame-
ters and classifies as "none" for no change, "low" if there
are changes in 2 categories, "medium" for changes in 3
categories and "high" for changes in more than 3 catego-
ries. The six categories evaluated are: Gadolinium enhanc-
ing lesions, new T2 lesions, T2 burden of disease, new T1
lesions, T1 burden of disease and brain atrophy.
This information is stored and can be shown on-screen to
graphically illustrate the evolution of the risk reports on a
given patient and his or her tendency to maintain or
worsen disease status.
Clinical assessments
TORs were applied retrospectively to our patients. The cri-
teria used were based on the CMSWG modified analog
model, but imaging data were not considered because
MRI was not performed in all cases, following Freedman
et al recommendation when MRI is no available [4].
Patient data were assessed during year 1 for disease activ-
ity by relapse and progression rate, and subjects were
assigned to two groups according to TOR. The levels of
concern were "change treatment" (CH) and "no change
treatment" (NCH). According to the analog model, if all
three items were "low", two of them were "medium" or
any one of them was "high", then it was likely that treat-
ment response might be suboptimal and patients were
therefore assigned to the "change treatment" group.
These assessments were then compared to observed clini-
cal outcomes for disease activity over the following years.
Patients were evaluated until the neurologist decided to
change or discontinue the immunomodulatory treat-
ment.
To evaluate the patient evolution in each group, the
number of relapses per year and EDSS were calculated for
each year (2nd, 3rd, 4th and 5th) and patient, and the means
for each group (CH or NCH) were compared. We alsoBMC Neurology 2008, 8:3 http://www.biomedcentral.com/1471-2377/8/3
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used the relapse rate and the progression rate for the inter-
val of 4 years (2nd to 5th), to compare both groups.
Statistical analysis
Data were processed using the SPSS version 11.0.0 statis-
tical package, and a descriptive and analytical statistical
analysis was carried out.
The mean, standard deviation (SD), median, and the
upper and lower quartiles were used for the description of
numerical variables. A comparison between the "change
treatment" (CH) group and the "no change treatment"
(NCH) group was made in relation to relapse and progres-
sion data, using univariate analysis of variance (ANOVA).
The sensitivity of the algorithm was calculated as the
number of patients considered as CH (need for change)
by the tool amongst the total population of patients con-
sidered as non-responders after the evolution period.
The specificity of the algorithm was calculated as the
number of patients who responded to treatment in rela-
tion to the patients considered as NCH ("no need for
change").
Results
Subject demographics and clinical parameters
We have data on 55 patients (10 males, 45 females)
assigned to therapy with IFN beta 1a IM for 51 months
(range 18 – 84). Data from other DMTs were excluded due
to the required homogeneity in therapy in a validation
study of treatment response criteria. The mean number of
relapses within the previous two years was 2.5 (range 2–
7), and the baseline EDSS was 1.8. "Change treatment"
(CH) status was assigned to 22/55 patients (40%), and
"no change treatment" (NCH) to 33 patients (60%).
Table 1 displays the demographic and clinical characteris-
tics of the two patient populations, showing no differ-
ences in baseline characteristics.
The number of patients analysed in each period were 55
in the 1st and 2nd year, 44 in the 3rd year, 34 in the 4th, and
23 in the 5th year. During the first two years of therapy
(one year before and one year after optimization), all
patients continued with the same treatment, dose and
route of administration. During the third year, 10 patients
switched treatment, versus 12 and 9 patients in the fourth
and fifth years, respectively. At the end of the follow-up
period, 9 out of 22 (41%) patients of the NCH group and
14 of 32 (44%) of the CH group continued with the same
treatment, dose and route of administration. These differ-
ences were not statistically significant. In those cases
where treatment was changed to a higher dose, this was
not attributable to side effects; but rather, from the appli-
cation of the treatment criteria of the Andalusian health
authorities to the clinical evolution parameters in relation
to relapses and progression. Despite this, there were no
losses in terms of patient follow-up. All patients initially
evaluated continued follow-up at the MS Unit with the
same or different therapy.
Sensitivity and specificity
The estimated sensitivity according to the last visit status
of every patient was 73.9%. In turn, specificity was 84.4%,
and the positive predictive value was 77.3%.
Relapse rate during year 2–5
Figure 1 shows the mean number of attacks during the
complete period (2nd  to 5th  year). The differences
appeared after the second year (0.52 ± 0.67 vs. 0.39 ± 0.7,
p = 0.5, CH vs. NCH, respectively), and increased after the
third year (0.61 ± 0.77 vs. 0.34 ± 0.68, p = 0.24 CH vs.
NCH, respectively) and fourth year (0.60 ± 0.51 vs. 0.26 ±
0.56, p = 0.07 CH vs. NCH, respectively), but were not sta-
tistically significant until the 5th year (0.7 ± 0.66 vs. 0.07 ±
0.26, p = 0.001 CH vs. NCH, respectively).
On considering the global follow-up period of those
patients who completed follow-up until the 5th year with-
out changing treatment, and the period covering from
years 2 to 5, the differences were seen to be clearly signif-
icant (CH: 1.72 ± 1.58, NCH: 0.85 ± 1.20, p = 0.02).
Progression during year 2–5
On analyzing EDSS progression (Figure 2), we observed a
statistically significant difference from the second year
onwards (3.47 ± 1.45 in the CH group vs. 2.37 ± 1.17 in
the NCH group, p = 0.003). This difference was main-
Table 1: Clinical data of patients before treatment in both groups (p > 0.05)
CHANGE (CH) No Change(NCH)
Number 22 33
Time to treatment (months) 52.5 51.2
EDSS before treatment 1.86 1.87
Attacks 2 yr. before treatmen 2,7 2.3
Attacks 1 yr. before treatmen 1.9 1.9
Age at onset 27.3 27.0
Duration of disease 13.7 12.6BMC Neurology 2008, 8:3 http://www.biomedcentral.com/1471-2377/8/3
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tained after the third (3.86 ± 1.67 in the CH group vs. 2.57
± 1.54 in the NCH group, p = 0.01), fourth (4.42 ± 1.69
in the CH group vs. 2.63 ± 1.54 in the NCH group, p =
0.003) and fifth year of follow-up (4.28 ± 1.6 in the CH
group vs. 2.68 ± 1.7 in the NCH group, p = 0.04). The
annual progression rate (EDSS points/year) from the 12-
month visit to the last visit was higher in the group
"change treatment" as compared to the "no change treat-
ment" group (CH: 0.29 ± 0.34, NCH: 0.13 p = 0.03).
Discussion
The lack of criteria for DMT efficacy in MS is an important
and unresolved issue. Several DMTs are now available for
the treatment of MS, and have been shown to alter the
clinical course of the disease by decreasing activity and
delaying the progression of disability. Nevertheless, many
patients continue to experience disease activity whilst on
treatment, and recommendations have been made on
how the success of therapy in an individual patient can be
assessed. However, even after having identified criteria for
a suboptimal response to current treatments, clinicians
require guidance on how to improve the outcomes [5].
First Bashir et al. [6] and subsequently a consensus group
[1] addressed this problem with objective clinical criteria.
The main recommendation of this consensus group is to
collect data as soon as possible, in order to allow neurol-
ogists to change therapy when treatment is considered to
be ineffective. With our program, the Canadian group cri-
teria can be applied prospectively, easily and objectively.
In our study, patients treated with interferon beta 1a IM,
30 mg/week, might potentially be considered as candi-
dates for treatment change according to TOR, after one
year of treatment and without including MRI data. The
results presented by Freedman et al [4] were different
when Rebif 22 was used, and only 10–12% of 362
patients were considered to be candidates for change.
The annualized relapse rate of those patients on Avonex
from year 2 to year 5 was 1.72 for those assigned to the
"CH treatment group" and 0.84 for these assigned to the
"NCH treatment group". In the work of Freedman et al.,
the combined annualized relapse rate for patients on
Rebif 22 or 44 during years 2 to 4 was 0.48 for those with
no or low concern during year 1, and 1.12 for those
assigned to medium or high concern. Most patients in
both subgroups treated with Rebif (48% on 22 mg dose
and 53% on 44 mg dose) assigned to the high concern sta-
tus had more than one attack per year. These results are
similar to our own data. The differences in the classifica-
tion of the status of concern, and the different doses and
route of administration of interferon beta 1a may make
difficult additional comparisons between the study by
Freedman et al. and our own data.
Relapse rate during year 0 – 5 (95% Confidence Interval) Figure 1
Relapse rate during year 0 – 5 (95% Confidence Interval).
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Our data showed that treatment optimization recommen-
dations applied at the end of the first year of therapy based
exclusively on clinical outcomes are useful to predict a
high level of clinical activity (relapses and disability), with
a high sensitivity and specificity.
Surprisingly, in our study the tool showed to be more
effective in predicting EDSS progression rather than
changes on the relapse rate. At the end of the first year of
follow-up (2nd year after the start of treatment), when all
54 patients continued with the same treatment, the differ-
ence on EDSS was already seen (3.47 points in the high
risk group versus 2.37 points, with a high level of statisti-
cal significance, p = 0.003, after the second year). At the
end of the third year, the difference was similar, though
the level of statistical significance decreased because 10
patients changed treatment and were not considered in
the statistical analysis. After the third year, the differences
proved to be stable, although the level of statistical signif-
icance decreased further still, because of the fewer remain-
ing patients in the sample (Figure 2).
We lost a similar number of patients in both groups, and
we are unable to explain this observation. In fact, we
expected to have more losses in the CH group because of
a poorer disease evolution. Anyhow, it is clear that those
patients considered by the algorithm as candidates for
change, who continue with the same treatment, are at
high risk of a poorer course than those considered as non-
candidates for change.
The lack of significant differences on the relapse rate until
the fifth year of treatment can be due to the fact that a clear
reduction of the relapse rate was observed in both groups.
Freedman et al. [4] found no statistically significant differ-
ences on EDSS parameters from years 2 to 4, though it is
necessary to point out that 19% of the patients treated
with Rebif 22 and only 5% of those treated with Rebif 44
progressed more than 1 point for EDSS. The differences in
the dose, route and frequency of administration of IFN-
beta 1a of Avonex and Rebif, could partly explain these
differences.
Progression of disability from year 2 to year 5 Figure 2
Progression of disability from year 2 to year 5. (95% Confidence Interval, EDSS: Expanded Disability Status 
Scale).
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We agree with Freedman et al. that TOR is a good tool for
monitoring the treatment response to DMT in MS
patients. Our program is easy to use and not time-con-
suming, and therefore can help neurologists to evaluate
patients objectively and easily.
We think that additional items can be explored as poten-
tial predictors of treatment response, such as cerebrospi-
nal fluid parameters, IgG synthesis [7], IgG or IgM
oligoclonal bands [8,9], and anti-interferon beta antibod-
ies, and can also be included in new versions of the soft-
ware, in addition to MRI parameters.
Study limitations
One of the limitations of the study might be the fact that
is based on a post-hoc analysis. Even though the clinical
data (EDSS score and relapse rate) were obtained prospec-
tively, the optimization criteria were recorded in a retro-
spective way in the software.
Another limitation could be the fact that the sample size
was too small to draw strong conclusions.
In this study we have a pre-treatment control period of
two years. This period could be considered to be longer
than required, since such a long pre-treatment period
could underestimate the annualized relapse rate. If we
would use a control period of one year, it is likely that
fewer patients would be considered as candidates to
change (CH), because the pre-treatment relapse rate
would be higher. But we do not think that this fact modi-
fies the results from our study. Nevertheless, we consider
that in the future, new prospective studies with different
pre-treatment control periods (one to three years) should
be conducted.
We have shown that TOR, is a good tool for monitoring
the response to DMT in MS patients, and can help opti-
mize treatment. Our program would help neurologists in
clinical practice, because it is not time-consuming and
easy to apply – providing a tool for objective and simple
patient assessment. Optem also can be a useful tool for
prospective follow-up studies.
Conclusion
1. Treatment optimization recommendations is a good
tool for monitoring the treatment response to DMT in MS
patients: Our data showed that TOR applied at the end of
the first year of therapy based exclusively on clinical out-
comes are useful to predict a high level of clinical activity
(relapses and disability), with a high sensitivity and spe-
cificity.
2. Our program is easy to use and not time-consuming,
and therefore can help neurologists to evaluate patients
objectively and easily.
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